Skip to content
Medical Health Aged Care

Ramsay Health Care to expand into the ACT with National Capital Private Hospital

Ramsay Health Care 2 mins read
Key Facts:
  • Ramsay Health Care to acquire National Capital Private Hospital in Canberra for $251 million, marking its first ACT investment
  • Transaction completion expected mid-2026, subject to regulatory approvals
  • Patient care will continue as normal during the transition period, with focus on maintaining stability for hospital employees and doctors

Australia’s leading private hospital operator, Ramsay Health Care, has agreed to acquire National Capital Private Hospital in Canberra.

Ramsay Health Care Group CEO Natalie Davis said the $251 million deal was an important and exciting milestone for the group and marked Ramsay’s first hospital investment in the ACT.

"National Capital Private Hospital has a highly regarded clinical and operational team with deep connections to the ACT health community," Ms Davis said.

“The hospital has a strong reputation for clinical quality, patient safety and strong doctor partnerships. Ramsay shares those priorities and we look forward to supporting the hospital’s continued growth over the long term.”

Located next to Canberra Hospital and the Australian National University Medical School, National Capital Private Hospital plays an important role in the region’s health system, with particular expertise in cardiac care, orthopaedics and oncology.

“This acquisition reflects our focus on hospitals that deliver quality high acuity care, serve established communities and have strong foundations to support clinical development and training,” Ms Davis said.

“Working closely with Canberra Health Services and the National Capital Private Hospital team, we see real opportunity to further develop the services and reputation of this leading health precinct.”

Subject to regulatory approvals, Ramsay expects to take over operation of National Capital Private Hospital in mid-2026.

Over the coming months, Ramsay will work closely with the hospital team and Healthscope to plan a smooth and well-managed transition, including workforce, clinical, operational and technology requirements. For patients, care will continue as normal while the transition progresses.

“Our priority is continuity of care for patients and maintaining stability for the hospital team and doctors,” Ms Davis said. “We look forward to welcoming them to Ramsay and sharing our long-standing purpose of ‘people caring for people’.”

About Ramsay Health Care

Ramsay Health Care is Australia’s leading private hospital operator, with a strong reputation for clinical excellence, patient safety and trusted partnerships with doctors. Guided by our purpose of ‘people caring for people’, we continue to invest in clinical capability, innovation, workforce development and patient experiences to support strong health outcomes and sustainable health systems.

Find out more: ramsayhealth.com.au  


Contact details:

Barbara Cox - Chief Communications Officcer - 0403 090 913

Emily Fardoulys - Head of Strategic Communications - 0455 066 764

Media

More from this category

  • Medical Health Aged Care, Research Development
  • 13/01/2026
  • 14:06
Centre for Healthy Brain Ageing (CHeBA), UNSW Sydney

Simple tool predicts who is most at risk of dementia after stroke

A new international study led by researchers from UNSW Sydney’s Centre for Healthy Brain Ageing (CHeBA) has developed the first practical, five-year dementia risk…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 13/01/2026
  • 10:50
Nova Eye Medical (ASX:EYE)

Nova Eye Medical Reports Record Sales Result for December 2025 Quarter

HIGHLIGHTS Record December quarter with global sales of US$6.1 million, up 38% on pcp and 25% on the September 2025 quarter Global six-month sales…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 13/01/2026
  • 10:09
Jane Morgan Management

NeuroScientific Biopharmaceuticals (ASX:NSB) Reports Clinical Response for StemSmart(TM) Treatment in Fistulising Crohn’s Disease Under Special Access Program

13 January 2026 – Perth, Australia | NeuroScientific Biopharmaceuticals Limited (ASX:NSB) has today announced a “Clinical Response” from patients treated with its patented StemSmart™ Mesenchymal Stem Cell (MSC) therapy under the Therapeutic Goods Administration’s (TGA) Special Access Scheme (SAS) for fistulising Crohn’s disease. Three of four patients treated in Cohort 1 of the Special Access Program demonstrated a successful “Clinical Response” following treatment with StemSmart™, with the fourth patient showing a partial response with further clinical assessment needed. A Clinical Response is defined as either closure of at least 50 per cent of fistula openings or a reduction in fistula…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.